Collunovar 0.11%

Quick links

Choose a section

Quick links to important sections

Advertisements

Collunovar 0.11%

Advertisements

Overview of Collunovar 0.11%

Quick Facts

Property Description
Active ingredient Chlorhexidine Gluconate
Form Solution for buccal spray
Pharmacological class Antiseptic antibacterial agent
General purpose Local microbial control in the mouth and throat
Origin Synthetic (Biguanide compound)

What Type of Medicine is Collunovar 0.11%?

Collunovar 0.11% is a medicinal product whose high-level classification is as an antiseptic antibacterial agent, defined by the precise concentration of the primary active substance. The product is functionally categorized as a topical antimicrobial, meaning its effect is localized at the site of application within the mouth and throat, ensuring a targeted action rather than systemic absorption. This preparation is clinically recognized for its reliable germ-reducing capacity, which supports its use in various oral hygiene contexts. Collunovar 0.11% is a single-active ingredient product, focusing solely on the established properties of its main component to achieve local germ control.

Active Ingredient and Preparation: Chlorhexidine Gluconate 0.11%

The primary component of Collunovar 0.11% is the active ingredient, Chlorhexidine Gluconate (a salt of Chlorhexidine), presented at a specific concentration of 0.11%. This compound is a synthetic derivative belonging to the biguanide chemical class, known for its ability to adhere to mucosal tissues and provide sustained action. The preparation is manufactured as a solution for buccal spray, a liquid dosage form specifically formulated for oral/oropharyngeal/topical mucosal administration via a fine mist. This spray format is a differentiating factor, positioning it as a tool for targeted application in contrast to broader oral rinses.

General Purpose of This Topical Antimicrobial Solution

The core purpose of this spray solution is to provide localized antimicrobial activity for the hygienic management of the oral and pharyngeal environment. This function stems from the compound's mechanism, which involves disrupting the cell walls of susceptible bacteria and other microbes, leading to a germicide effect. Studies confirm that Chlorhexidine possesses a broad-spectrum antimicrobial action against a range of microorganisms. By delivering this concentrated, antiseptic action directly to the mucosal tissues, the preparation supports the reduction of the local microbial load, a typical use scenario when temporary oral hygiene support is needed.

Regulatory References

  1. Chlorhexidine in Dentistry: Pharmacology, Uses, and Adverse Effects (NIH/PMC)
Advertisements

What side effects are possible with Collunovar 0.11%?

Possible Side Effects and Safety Information

The safety profile for Collunovar 0.11% (Chlorhexidine Gluconate) is defined primarily by expected local effects related to its topical action and the potential for rare, serious immune system reactions, as documented in official regulatory labeling.

Adverse Reaction Classification

Adverse reactions are classified based on reported frequency, predominantly affecting the oral cavity and immune system:

Classification System-Organ Class Involved Documented Effects
Common / More Common Gastrointestinal / Oral System Staining of oral surfaces (teeth, tongue, restorations); alteration in taste perception (dysgeusia); increased formation of dental calculus (tartar).
Rare / Frequency Not Known Immune System Disorders Serious generalized allergic reactions, including hypersensitivity and anaphylaxis.

Time-related regulatory notes indicate that staining is typically associated with prolonged or long-term use, while altered taste perception may become less noticeable with continued administration.

Serious Safety Considerations

The most serious safety consideration, though rare, is the potential for anaphylaxis or severe allergic reactions. The product is contraindicated and should not be used in individuals with a known sensitivity or allergy to chlorhexidine gluconate or any of its components.

Population-Specific Safety Statements

Official regulatory documents note specific considerations for certain populations:

  • Pediatric Use: Safety and effectiveness have not been formally established in regulatory documents for children under 18 years of age.
  • Pregnancy/Lactation: Caution is advised; use is recommended only if clearly needed due to limited official data on human risk or excretion in breast milk.

This structure ensures adherence to the regulatory safety framework, detailing official adverse events and necessary constraints without providing clinical advice or instructions.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose Manifestations

The officially documented presentations of overdose pertain primarily to accidental ingestion of large volumes of the solution. Since the active ingredient, Chlorhexidine Gluconate, is poorly absorbed systemically from the gastrointestinal tract, ingestion may result in localized irritation of the gastric mucosa and symptoms such as nausea.

Severe Outcomes and Emergency Action

Severe outcomes are linked to hypersensitivity reactions, which mandate immediate emergency care. The regulatory labels indicate that rare but life-threatening anaphylactic shock has been reported. Symptoms that require urgent action include wheezing or difficulty breathing, swelling of the face or oropharyngeal tissues, severe rash, or signs of shock. Users are officially required to seek immediate medical attention and call emergency services if any of these severe signs develop, and stop using the product immediately.

Management and Monitoring

Management of ingestion or severe reactions is defined as symptomatic and supportive treatment, as no specific antidote is known. Hospitalization or continuous monitoring in an emergency setting is required for severe cases. Specific guidance exists for small child ingestion, noting that ingestion exceeding a threshold volume (e.g., approximately four ounces of a 0.12% solution) may warrant medical attention, especially due to the potential for alcohol intoxication from excipients.

Advertisements

Therapeutic Uses of Collunovar 0.11%

What Collunovar 0.11% Treats: Main Uses and Benefits

Collunovar 0.11% is commonly used across conditions presenting with acute episodes of gum disease, such as gingivitis, and other localized plaque-induced inflammatory diseases. It helps address symptom clusters related to inflammatory or irritative states. Specifically, it is relevant for managing symptoms that interfere with daily comfort, such as the redness, swelling, and bleeding of the gums. The antiseptic support contributes to improved comfort during periods of heightened gum distress. Primary uses focus on addressing gingivitis, mouth inflammation, and minor infections like localized sore throat or denture stomatitis.

The product is applied in clinical settings that involve acute or unstable symptom patterns, such as those that follow minor oral surgical procedures like tooth extractions. It supports the patient during difficult episodes by easing distress in contexts where additional symptomatic support is needed. This focus on comfort is central to its therapeutic role:

“The spray offers symptomatic relief that may help patients cope more steadily with episodes of heightened discomfort related to symptoms of inflammation.”

It assists with maintaining functional stability and contributes to improved day-to-day comfort during symptomatic periods in scenarios where short-term symptomatic assistance is important.


Quick Fact: Relief for Localized Oral Symptoms
Primary Indication Focus Symptoms of gingivitis (gum inflammation)
Key Symptom Relief Bleeding, swelling, and redness of the gums
Common Clinical Context Post-procedural care and acute local inflammation
Patient Benefit Assists with comfort and maintaining functional stability during episodes of distress

Regulatory References

  1. NIH MedlinePlus overview on Chlorhexidine Gluconate
Advertisements

Eligibility and Restrictions for Use

Eligibility for Collunovar 0.11% (Official Regulatory Information)

Official regulatory documents define specific populations who are permitted, restricted, or prohibited from using Collunovar 0.11%. Eligibility is primarily established for adults 18 years of age and older for labeled uses.


Absolute Contraindication

Category Regulatory Statement
Prohibited Users Collunovar 0.11% is contraindicated in patients with a known hypersensitivity to Chlorhexidine Gluconate or to any other component present in the formulation.

Age-Related and Conditional Restrictions

Population Group Eligibility Status
Pediatric Patients Use in those under 18 years of age is not recommended; clinical effectiveness and safety have not been established by regulatory authorities.
Pregnant/Nursing Use is conditional and only permitted if clearly needed, due to a lack of adequate, controlled studies in these specific populations. Caution is advised for nursing individuals.
Geriatric Patients Use is not prohibited, but clinical studies included insufficient numbers of older adults to determine whether they respond differently than younger adults.

These official statements delineate the specific constraints imposed by government health authorities regarding the use of this medicine.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interaction Scope

The official interaction profile for Collunovar 0.11% (Chlorhexidine Gluconate) is primarily defined by local administration-timing requirements and formulation incompatibility, rather than systemic drug–drug interactions. Due to the active ingredient's minimal systemic absorption, regulatory documents do not list interactions involving metabolic enzymes (like CYP450) or drug transporter systems.

Local and Timing-Based Interactions

The most relevant documented interactions concern substances that affect the product's local action in the mouth:

  • Product Inactivation: Chlorhexidine Gluconate is chemically incompatible with anionic agents, such as surfactants commonly found in conventional toothpastes. Co-administration or immediate sequential use of anionic compounds may lead to the local neutralization and decreased effectiveness of the active ingredient.

  • Physical Removal: The product's retention and sustained local effect are compromised by rinsing or ingestion. Regulatory guidance strictly advises against the immediate rinsing with water or other mouthwashes following use, and restricts the immediate consumption of food or beverages. These restrictions are in place to prevent the physical removal of the medicine from the oral tissues.

Regulatory Restrictions

While no specific systemic medicinal product is listed as interacting, the product is strictly restricted from use in individuals with a known hypersensitivity to Chlorhexidine Gluconate or any other component in the formulation, as stated in prescribing information.

Advertisements

Mechanism of Action

Direct Chemical Disruption of Microbial Cell Structures

The mechanism involves the cationic (positively charged) structure of Chlorhexidine Gluconate electrostaticaly binding to the negatively charged components of the bacterial cell surface. This binding rapidly increases the cell membrane's permeability, leading to the leakage of essential internal components and the eventual coagulation of cytoplasmic proteins. This direct chemical damage results in the rapid, non-specific inhibition of microbial cellular function.


Tissue Adsorption and Substantivity

The mechanism is characterized by the drug's inherent property of substantivity, where it binds reversibly to the oral and pharyngeal mucosal tissues. This tissue reservoir ensures the molecule is not immediately cleared by saliva but is slowly and continuously released back into the local environment. This process maintains a local concentration gradient, resulting in the sustained presence of the active molecule on the applied area.

Advertisements

Dosage and Administration Information

How to Use Collunovar 0.11%: Official Usage Patterns

Collunovar 0.11% is used based on high-level, structured administration principles defined for topical oral antiseptics. This product is strictly limited to topical mucosal administration in the oral cavity and oropharynx, delivered via the buccal spray solution.

The standard pattern requires the solution to be administered twice daily—typically once in the morning and once in the evening. Application should occur after a patient’s usual dental hygiene routine, such as brushing. The dose volume must be maintained in contact with the oral tissues for approximately 30 seconds to ensure adequate exposure of the active component. After the contact period, the solution must be expectorated; it is not intended for ingestion.

A key procedural condition involves the immediate post-application period. Patients are strictly instructed not to consume food or beverages, nor to rinse with water or any other mouthwash immediately after use. This preserves the necessary retention of the active agent on the mucosal surfaces.

Usage of this medicine is classified as short-term. Continuation of the course requires a professional dental reevaluation and prophylaxis at intervals of no longer than six months to manage the underlying condition. Furthermore, the official labeling states that use is not recommended for pediatric patients under 18 years of age, as clinical safety and effectiveness have not been established in this group.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Collunovar 0.11%


Evidence for Studies Focused on Gingivitis and Plaque Control

The active ingredient in Collunovar 0.11% was studied for symptoms of gingivitis and the management of dental plaque in research exploring how symptoms change over time. This evidence primarily comes from Randomized Controlled Trials (RCTs), where study groups were compared against a control. These trials monitored outcomes using objective clinical scales (Plaque and Gingival Indices) to measure inflammation and bleeding. Findings describe patterns observed over several weeks; however, most research used oral rinse formulations, not the specific 0.11% spray. Long-term effects are not fully established, and follow-up data beyond a few months are limited.


Evidence for Studies Supporting Post-Procedural Oral Care

The agent was evaluated in research settings involving minor oral surgical procedures, such as tooth extractions. Research examined its role in post-operative care by monitoring complications like alveolar osteitis (dry socket). Systematic reviews reported patterns related to incidence rates for certain post-procedural complications in the studied groups. Research insights are typically restricted to the acute post-operative phase (one to two weeks). Furthermore, comparative evidence is lacking for the 0.11% spray form compared to other local delivery methods, as the research base includes various concentrations and forms (rinses, gels).


Assessing Research Gaps and Patient Groups

The research base includes a large volume of evidence regarding the active ingredient’s use in conditions characterized by fluctuating symptoms, with strong reliance on RCTs and meta-analyses. However, the results apply only to the populations studied (mostly general adults). Data for specific groups, such as children or patients with comorbid conditions, are limited. This overview highlights that the main uncertainty lies in the generalization of findings from older mouth rinse studies to the distinct 0.11% buccal spray formulation.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Collunovar 0.11% (FAQ)

Q: What is Collunovar 0.11% used for in simple terms?

Collunovar 0.11% is an antiseptic solution used for the local control of bacteria in the mouth and throat. According to official labeling, its primary purpose is to help treat gingivitis (gum disease) and manage dental plaque. It may also be used to support gum healing following minor oral surgical procedures.

Q: Is Collunovar 0.11% a type of steroid medicine?

No, Collunovar 0.11% is not a steroid. Regulatory documents classify it as an antiseptic antibacterial agent. It contains Chlorhexidine Gluconate, which is a type of synthetic biguanide compound that works by disrupting bacterial cell structures.

Q: What is the difference between Collunovar 0.11% and similar medicines?

The primary difference lies in the method of application. Official product descriptions state that Collunovar 0.11% is a solution formulated specifically as a buccal spray. This delivery method is designed for more targeted application to the oral and pharyngeal mucosal tissues, unlike traditional, broader oral rinses.

Q: How quickly does Collunovar 0.11% usually start working?

While patient-perceived changes may vary, studies and official product information describe the active ingredient's bactericidal (germ-killing) effect as rapid. This quick action is due to the chemical binding quickly disrupting the structure of bacterial cell surfaces.

Q: Are there any known long-term side effects associated with Collunovar 0.11%?

Yes, the official safety profile notes that staining of the teeth, tongue, and dental restorations is typically associated with prolonged or long-term use. In rare instances, post-marketing reports have included permanent taste alteration. For this reason, official use is often limited to specific durations.

Q: Is it normal to feel a brief stinging or burning when first applying Collunovar 0.11%?

Regulatory safety information reports that some users may experience a temporary burning sensation or a mild peeling of the oral lining (desquamation). These effects are noted to sometimes become less noticeable with continued administration of the medicine.

Q: Is Collunovar 0.11% exactly the same as its generic version?

While generic products contain the same active ingredient and strength (0.11%), they may not be exactly the same. Official regulatory standards allow for differences in inactive ingredients (excipients), such as flavors or colorants, provided the products meet regulatory standards for therapeutic equivalence.

Q: Does Collunovar 0.11% affect my ability to drive or operate machinery?

Regulatory safety documentation does not list central nervous system effects such as drowsiness or dizziness associated with Collunovar 0.11% topical use. This finding is consistent with the drug having minimal systemic absorption (minimal amounts enter the bloodstream).

Q: What should be done if a recommended use of Collunovar 0.11% is missed?

Official regulatory consumer information suggests that an occasional missed use is generally not a cause for concern. The key factor is that the patient maintains regular compliance with the overall prescribed regimen.

Q: Can I apply other creams or lotions on the same area as Collunovar 0.11%?

The active ingredient is subject to regulatory caution due to chemical incompatibility with certain anionic agents found in products like toothpastes. Therefore, the use of other topical preparations immediately following Collunovar 0.11% is restricted to prevent the neutralization of the medicine's active effects.

Q: What happens in the body if too much Collunovar 0.11% is used?

If large amounts are accidentally ingested, regulatory documents warn this may cause symptoms of gastric distress such as nausea or stomach upset. Depending on the product's formulation, it could also potentially cause signs of alcohol intoxication. Official guidance states that medical attention should be sought immediately following accidental ingestion.

Q: Has Collunovar 0.11% been studied in different racial or ethnic groups?

Regulatory review of clinical trials for the active ingredient notes limitations regarding specific subgroups. The available data included insufficient numbers of patients in certain subgroups to establish whether their response to the medicine differs from the general adult population studied.

Q: Can Collunovar 0.11% cause difficulty sleeping or insomnia?

Difficulty sleeping or insomnia is not listed as a common or known adverse reaction in the regulatory documentation for the oral product. The product is designed for localized action with minimal systemic absorption.

Q: Is there a rebound effect when stopping Collunovar 0.11% suddenly?

Clinical studies tracking the long-term microbial environment found that the number of bacteria in dental plaque returns to baseline levels approximately three months after the medicine is discontinued. This indicates the sustained antibacterial effect does not persist indefinitely after stopping use.

Q: What does the term 'systemic absorption' mean for Collunovar 0.11%?

The term systemic absorption refers to the minimal amount of the active ingredient that transfers from the application site (the mouth) into the general bloodstream. Official labeling confirms that Collunovar 0.11% is designed for localized action, and only minimal amounts are absorbed into the body system.

Q: Why are official documents careful about the maximum duration of use for Collunovar 0.11%?

Official documentation limits the duration of use for Collunovar 0.11% for two main reasons. First, it is a safety measure to manage the increased risk of cosmetic side effects like staining with prolonged use. Second, it ensures the patient receives a required periodic professional dental reevaluation and prophylaxis to manage the underlying condition.

Q: Does Collunovar 0.11% have any known interaction with alcohol consumption?

Official regulatory guidance primarily focuses on avoiding immediate consumption of food or drink after use. It is noted that it is unknown if drinking alcohol systemically interacts with the oral medicine. Additionally, some formulations of the product may contain alcohol as an inactive ingredient.

Q: What is the average time it takes for Collunovar 0.11% to be cleared from the body (half-life)?

Clinical pharmacology studies found that detectable levels of the active ingredient were not present in the bloodstream 12 hours after use. This indicates the product is cleared relatively quickly from the body, with most of the elimination occurring through excretion in the feces.

Q: Can Collunovar 0.11% affect laboratory test results like blood sugar levels?

Regulatory documents do not list any known interactions or interference with common laboratory tests, such as blood sugar levels. This lack of interaction is consistent with the drug having minimal systemic absorption into the bloodstream.

Q: Why is it important to avoid using Collunovar 0.11% near the eyes?

Regulatory warnings state that contact with the eyes must be strictly avoided. The official safety information indicates that exposure of the solution to the eye has the potential to cause serious or irreversible damage to the cornea.

Q: What are the inactive ingredients in Collunovar 0.11% besides the active drug?

The official product label lists all ingredients, including the inactive components (excipients). While these may vary slightly by specific manufacturer, they commonly include purified water, alcohol, glycerin, flavor, and colorants.

Q: Has Collunovar 0.11% been the subject of any Drug Safety Communications from major health agencies?

Yes, the active ingredient has been the subject of a Drug Safety Communication issued by the FDA in 2017. This communication informs the public about the rare but serious risk of anaphylaxis (a severe, life-threatening allergic reaction).

Q: What is the risk of skin discoloration associated with Collunovar 0.11%?

Clinical testing showed that a measurable increase in staining on the anterior tooth surfaces was observed in 56% of users after six months of use. Of those, 15% were noted to develop what was classified as heavy stain.

Q: Why is Collunovar 0.11% often only prescribed for short courses of treatment?

Official documentation limits the use of Collunovar 0.11% to short courses primarily to minimize the risk of cumulative side effects, such as tooth and tongue staining. This limitation also ensures that patients receive the required periodic professional dental evaluations for their underlying condition.

Advertisements

How should Collunovar 0.11% be stored and disposed of?

Official Storage and Disposal Requirements

Regulatory documents define specific conditions for storing Collunovar 0.11% (a Chlorhexidine Gluconate solution) to maintain its stability and integrity.

Storage Component Official Requirement
Temperature Store at 20 C to 25 C (68 F to 77 F).
Prohibitions Do not freeze and protect the product from excessive heat.
Protection Keep the container tightly closed and protected from light.
Child Safety Keep out of the sight and reach of children and pets.
Disposal Dispose of the product and its container in accordance with local, regional, or national regulations.

Disposal instructions mandate avoiding release to the environment; the solution must not be poured into drains or waterways due to environmental toxicity concerns. All storage must be in the original container to ensure proper protection.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Collunovar 0.11% found in:

A-Z Index: